Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

In recent days, Recursion Pharmaceuticals reported positive early clinical data and advances in its AI-driven drug discovery pipeline, alongside a narrower-than-expected first-quarter EPS loss and ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

The stock looks cheap, but appearances can be deceiving.

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...